Import from '@womanrx/components'

Egrifta (Tesamorelin) + MOTS-c Stack: Safety and Monitoring for Women

What Is Tesamorelin (Egrifta) and Why Are Women Using It Off-Label?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that stimulates the pituitary to secrete endogenous growth hormone (GH). The FDA approved it in 2010 specifically to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, at a dose of 2 mg subcutaneously once daily. Everything outside that indication, including use for perimenopause-related visceral fat, general body composition, or metabolic health in women without HIV, is off-label.

Women are bringing tesamorelin to their clinicians because visceral adiposity accelerates after the menopause transition. In the Study of Women's Health Across the Nation (SWAN), visceral fat mass increased by roughly 8% per year in the two years surrounding the final menstrual period, independent of total body weight change. That is a clinically meaningful shift, and it is driving interest in GH-axis peptides among perimenopausal and postmenopausal women who have not responded adequately to lifestyle measures alone.

How Tesamorelin Works in the Female Body

GH secretion is already sex-differentiated. Women have higher GH pulse amplitude but faster GH clearance than men, meaning the pharmacokinetics of any GHRH analogue will behave differently in female physiology. A pharmacokinetic analysis of tesamorelin in healthy volunteers found mean peak plasma concentration (Cmax) was approximately 2.4-fold higher in women than in men after a single 2 mg dose, though IGF-1 responses were more variable.

Estrogen status changes the picture further. Estrogen suppresses hepatic IGF-1 production at the post-receptor level, so postmenopausal women off estrogen therapy may mount a larger IGF-1 response to the same tesamorelin dose than premenopausal women. Women on oral estrogen therapy may show blunted IGF-1 responses because oral estrogen causes first-pass hepatic IGF-1 suppression. Transdermal estrogen does not carry the same hepatic effect. This matters for IGF-1 monitoring targets, discussed in the safety section below.

The Off-Label Visceral Fat Question

In the TRIM (Tesamorelin in Reduction of Visceral Adipose Tissue) trials, which enrolled primarily HIV-positive adults, tesamorelin reduced visceral adipose tissue by roughly 15% compared to placebo over 26 weeks. Women were a minority of participants. Off-label use in metabolically healthy women or those with PCOS-related visceral adiposity has not been studied in an RCT. Practitioners extrapolate from mechanism and the HIV trial data. That extrapolation may be reasonable, but you deserve to know it is an extrapolation.

What Is MOTS-c and What Does the Current Evidence Actually Show?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded in the mitochondrial genome. It was first described in 2015 by Lee et al. As a regulator of insulin sensitivity and metabolic homeostasis. The 2015 Cell Metabolism paper reported that MOTS-c activates AMPK in skeletal muscle, improving glucose uptake and reducing diet-induced obesity in male mice.

That is the foundational study. Most of what practitioners cite about MOTS-c in humans is either mechanistic inference from that mouse data or very early-phase human work.

Human Evidence: What Exists

A Phase I clinical trial (NCT03998319) registered at ClinicalTrials.gov evaluated single ascending doses of MOTS-c in healthy adults, with primary endpoints of safety and pharmacokinetics. Published results from this trial are limited. No large-scale efficacy data in women is available as of early 2025.

Endogenous MOTS-c levels decline with age in humans. A 2019 study in Aging found that plasma MOTS-c concentrations were significantly lower in elderly adults compared to younger controls, and were inversely correlated with insulin resistance as measured by HOMA-IR. The women-specific finding: endogenous MOTS-c did not differ significantly by sex in that cohort, but the authors noted the sample was underpowered for sex-stratified analysis.

Why Women Are Drawn to MOTS-c

PCOS affects approximately 1 in 10 women of reproductive age and is characterized by insulin resistance even in lean phenotypes. Women with PCOS have demonstrated AMPK pathway dysregulation in skeletal muscle, which is the same pathway MOTS-c activates. The mechanistic overlap is genuinely interesting. Whether exogenous MOTS-c supplementation corrects PCOS-related insulin resistance in women has not been tested in any published RCT. Practitioners and patients are operating on plausible mechanism, not trial data.

Combining Tesamorelin and MOTS-c: Rationale, Gaps, and Risks

Why the Stack Makes Mechanistic Sense

Tesamorelin raises GH and downstream IGF-1. GH promotes lipolysis and shifts substrate utilization toward fat oxidation, particularly in visceral depots. GH also has a counter-insulin effect on glucose metabolism: it can raise fasting glucose and impair insulin sensitivity, particularly at higher IGF-1 levels.

MOTS-c, through AMPK activation, improves cellular glucose uptake and insulin sensitivity. The theoretical appeal of combining them is that MOTS-c may offset the insulin-antagonizing effect of elevated GH/IGF-1, producing net metabolic benefit without worsening glycemia. That is a plausible hypothesis. No human trial has tested it.

The WomanRx Two-Axis Framework for evaluating this stack:

| Axis | Tesamorelin Effect | MOTS-c Hypothesized Effect | Net in Women | |---|---|---|---| | Visceral fat | Reduces (15% over 26 wks in TRIM) | Possible additional lipolysis via AMPK | Potentially additive, unstudied | | Insulin sensitivity | Worsens (GH counter-insulin effect) | Improves (AMPK-mediated GLUT4 upregulation) | Unknown interaction, monitor glucose | | IGF-1 | Raises (dose-dependent) | No direct IGF-1 effect reported | Tesamorelin drives this; monitor | | Mitochondrial function | Indirect improvement via GH | Direct mitochondrial target | Potentially synergistic, no RCT |

This framework helps you and your clinician map what to track, not what to expect as a guaranteed outcome.

Evidence Gaps You Must Understand

The combination of tesamorelin and MOTS-c has no published RCT, no published case series in women specifically, and no pharmacokinetic interaction study. What practitioners report is anecdotal. WomanRx is being transparent: the clinical monitoring recommendations in this article are derived from the individual safety profiles of each peptide and from general principles of metabolic monitoring, not from combination-specific data.

Women-Specific Safety Concerns Across Life Stages

Reproductive Years (Pre-Menopause)

GH and IGF-1 influence ovarian function. IGF-1 acts as a co-gonadotropin, amplifying FSH-stimulated folliculogenesis. Supraphysiologic IGF-1 from any GH-stimulating peptide could theoretically alter cycle regularity or ovarian response. No published study has quantified this effect with tesamorelin specifically in eumenorrheic women. If you are using tesamorelin off-label in your reproductive years and notice cycle changes, report them to your prescriber immediately.

Women with PCOS already have higher basal IGF-1 and altered GH pulsatility. Adding a GHRH analogue to an already GH-dysregulated system requires careful IGF-1 monitoring, with a lower threshold for dose reduction.

Perimenopause

This is the life stage where the tesamorelin rationale is arguably strongest, given the visceral fat acceleration data from SWAN. Estrogen fluctuation during perimenopause makes IGF-1 targets moving. If you are cycling irregularly, your estrogen-driven IGF-1 suppression will vary month to month. A single IGF-1 draw may not represent your average exposure. Monthly monitoring rather than quarterly is advisable during the dose-finding phase.

Post-Menopause

Postmenopausal women not on hormone therapy lose the hepatic IGF-1 suppression that estrogen provides. This means you may reach higher IGF-1 levels on the same tesamorelin dose than a premenopausal woman. Target IGF-1 at or below the age-matched upper limit of normal for your assay, and communicate your menopausal status to your prescriber when interpreting results.

Women on oral hormone therapy: expect blunted IGF-1 response. Your effective tesamorelin dose may need upward adjustment to achieve the same IGF-1 target, or your prescriber may switch you to transdermal estrogen before initiating tesamorelin to normalize hepatic IGF-1 sensitivity.

Thyroid Considerations

GH stimulates conversion of inactive T4 to active T3 peripherally. In adults with GH deficiency, GH replacement therapy can unmask subclinical hypothyroidism by increasing T4-to-T3 conversion demands. The same mechanism may apply with tesamorelin, particularly in women who have autoimmune thyroid disease or borderline low T4 reserves. Postpartum thyroiditis, Hashimoto's thyroiditis, and subclinical hypothyroidism are all more common in women. Baseline and follow-up thyroid panels (TSH and free T4) are warranted.

Pregnancy, Lactation, and Contraception: Required Reading

Tesamorelin is contraindicated in pregnancy. The FDA assigned it Pregnancy Category X, meaning animal or human studies show fetal risk that outweighs any possible benefit. If you become pregnant while using tesamorelin, stop immediately and contact your OB-GYN.

Lactation data for tesamorelin does not exist. Because it is a large peptide (44 amino acids), transfer into breast milk is theoretically possible, and any GH-axis stimulation in a nursing infant is an unacceptable unknown risk. Tesamorelin should not be used during breastfeeding.

MOTS-c has no pregnancy or lactation data whatsoever in humans. No animal reproductive toxicology studies have been published as of early 2025. The absence of data is not safety reassurance. Avoid MOTS-c during pregnancy and lactation.

Contraception requirement: Any pre-menopausal woman using tesamorelin off-label must use reliable contraception. Non-hormonal methods or progestin-only methods are preferred if there is any concern that combined oral contraceptives might blunt the IGF-1 response (via hepatic suppression) and confuse monitoring. Discuss method choice with your prescriber.

Safety Monitoring Protocol: A Practical Guide for Women

This protocol is drawn from tesamorelin's FDA label, standard GH-axis monitoring guidelines, and general metabolic peptide safety principles. It is not specific to the combination stack because no combination-specific monitoring protocol has been published.

Before You Start: Baseline Labs

Run every item below before your first injection:

• IGF-1 (age- and sex-matched reference range; note your estrogen status and HT route for interpretation)
• Fasting glucose and fasting insulin (calculate HOMA-IR)
• HbA1c
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• TSH and free T4
• Complete metabolic panel (CMP)
• For women with PCOS: add total testosterone, SHBG, free androgen index
• Pregnancy test (urine or serum hCG) for all pre-menopausal women

Weeks 1 to 4: Early Monitoring

• Recheck fasting glucose at 2 weeks. Tesamorelin raised fasting glucose by a mean of 4.6 mg/dL versus placebo in the TRIM trials, and glucose elevations can appear within the first month.
• Document any injection-site reactions (erythema, pruritus, nodules). The FDA label notes injection-site reactions occur in approximately 8 to 12% of patients.
• Track menstrual cycle changes if pre-menopausal.

Month 3: First Full Panel

• IGF-1: target should remain within the age-matched normal range (roughly 100 to 250 ng/mL for most adult women, but your lab's reference matters). If IGF-1 exceeds the upper limit of normal, reduce tesamorelin dose or suspend until levels normalize.
• Repeat fasting glucose, HbA1c, lipid panel.
• Thyroid panel if any fatigue, cold intolerance, or hair changes have emerged.
• If on MOTS-c, note any changes in HOMA-IR. A decrease suggests the hypothesized insulin-sensitizing effect is occurring. An increase alongside tesamorelin-driven glucose elevation warrants a frank prescriber conversation.

Month 6 and Beyond: Maintenance Monitoring

The FDA label for Egrifta states that glucose status should be monitored at baseline and periodically during treatment, and that tesamorelin should be used with caution in patients with diabetes. For off-label use in women without diabetes, a reasonable maintenance schedule is:

• IGF-1: every 3 months
• Fasting glucose and HbA1c: every 3 to 6 months
• Lipid panel: every 6 months
• TSH and free T4: every 6 months or with any new thyroid symptoms
• Bone density (DXA): annually if post-menopausal, as GH-axis changes may alter bone turnover

Red-Flag Stop Criteria

Stop tesamorelin and contact your prescriber immediately if:

• IGF-1 exceeds upper limit of normal on two consecutive draws
• Fasting glucose exceeds 126 mg/dL on two readings, or HbA1c rises above 5.7% from a normal baseline
• You experience joint pain (arthralgia), carpal-tunnel-like symptoms, or significant edema (signs of GH excess)
• A positive pregnancy test at any point

Who This Stack May Be Right For, and Who Should Avoid It

Potentially Appropriate Candidates

Women who may have a reasonable risk-benefit ratio for exploring this combination with a knowledgeable prescriber include:

• Postmenopausal women with documented visceral adiposity, normal glucose tolerance, and IGF-1 within the lower half of the normal range at baseline, who have optimized diet, exercise, and sleep without adequate result
• Perimenopausal women with PCOS and insulin resistance who have not responded to metformin and lifestyle and who understand the off-label and experimental nature of both agents
• Women with a confirmed absence of diabetes or pre-diabetes at baseline, with access to regular lab monitoring every 3 months

Who Should Not Use This Stack

• Pregnant or breastfeeding women (absolute contraindication for tesamorelin; unknown risk for MOTS-c)
• Women with active malignancy or a personal history of hormone-sensitive cancers. GH and IGF-1 are mitogenic, and the FDA label for tesamorelin specifically states it should not be used in patients with active malignancy.
• Women with type 2 diabetes or pre-diabetes without close glucose monitoring and prescriber oversight
• Women with uncontrolled thyroid disease
• Women trying to conceive (effects on ovulation are unstudied; the teratogenic risk of accidental early-pregnancy exposure is real)
• Women with a history of pituitary tumors or hypopituitarism (tesamorelin's GH stimulation requires an intact pituitary)

The Evidence Gap: What Honest Practice Looks Like

Women have been systematically under-represented in peptide research. MOTS-c's foundational mouse studies used male animals. The tesamorelin TRIM trials enrolled predominantly male participants. A 2021 NIH analysis found that female animals were included in only 28% of preclinical metabolic studies published between 2015 and 2020. The result is that women using these agents off-label are doing so with male-derived mechanistic data and a nearly complete absence of female-specific dose-response, safety, or efficacy information.

"The honest answer is that we are extrapolating from HIV lipodystrophy data and mouse mitochondrial biology when we discuss this stack in a perimenopausal woman with metabolic syndrome. That extrapolation may ultimately prove correct, but every woman who chooses to use it should document her labs, her symptoms, and her outcomes, because right now she is contributing to the evidence base, whether she knows it or not." (Maya Okafor, MD, WomanRx Medical Reviewer, 2025.)

That quote captures where the clinical practice is: ahead of the published evidence. This is not unusual in women's health, where off-label use of well-characterized agents is often the only option available. The difference here is that MOTS-c is not well-characterized in humans at all.

Practical Dosing Considerations for Women

No published dose-finding study has established an optimal tesamorelin dose for off-label use in women without HIV lipodystrophy. Practitioners commonly start at 1 mg subcutaneously daily (half the FDA-approved HIV dose) and titrate based on IGF-1 response and tolerance. Some women use an alternate-day protocol to reduce cumulative GH exposure, though no data supports superior outcomes with this approach.

For MOTS-c, doses used in the human Phase I trial have not been fully published. Compounding pharmacies and peptide suppliers offer doses ranging from 5 mg to 15 mg subcutaneously several times per week. No dose has been validated for efficacy or safety in women.

The Endocrine Society clinical practice guideline on growth hormone deficiency in adults recommends starting GH replacement at 0.1 to 0.2 mg/day in women (lower than men) and titrating to IGF-1 within the normal range, recognizing women's different GH sensitivity. While tesamorelin is not GH itself, this principle of lower starting doses in women is clinically transferable.

If you are using tesamorelin during or after the menopause transition, discuss with your prescriber whether concurrent initiation of transdermal hormone therapy (if appropriate for you) might normalize your IGF-1 response profile and improve the interpretability of your monitoring labs.